Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOVENT vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
40% bound primarily to albumin.
65% bound to albumin
0.3-0.5 L/kg, approximating total body water.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96%; sustained-release: 80-90%.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR 30-50 m L/min: reduce dose by 25%. GFR 10-29 m L/min: reduce dose by 50%. GFR <10 m L/min: reduce dose by 75% or extend interval to every 24 hours.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75% or consider alternative therapy.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Oral: 5-10 mg/kg every 12 hours; maximum 400 mg/day. Intravenous: 5 mg/kg loading dose, then 5 mg/kg every 12 hours.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Initiate at 200 mg every 12 hours; increase cautiously to 400 mg every 12 hours; monitor renal function and adjust per renal guidelines.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
High risk of toxicity with narrow therapeutic index; monitor serum levels,Use caution in patients with cardiac disorders (e.g., arrhythmias), liver disease, renal impairment, seizure disorders, or peptic ulcer disease,Drug interactions with fluoroquinolones, macrolides, cimetidine, allopurinol, and others can increase theophylline levels,Cigarette smoking and certain anticonvulsants can decrease theophylline levels
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component,Seizure disorder not adequately controlled,Active peptic ulcer disease
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid high-fat meals as they can alter absorption of sustained-release formulations. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) may increase the risk of toxicity and should be limited. Charcoal-grilled foods and a high-protein diet may reduce theophylline clearance, while a high-carbohydrate diet may increase clearance; maintain consistent diet.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnancy category C.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Excreted in breast milk; M/P ratio approximately 0.6; use with caution, monitor infant for irritability and tachycardia.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Increased clearance in late pregnancy may require dose increase; monitor serum levels and adjust to maintain therapeutic range (5-15 mcg/m L).
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
THEOVENT is a brand of theophylline, a methylxanthine bronchodilator. Narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Caffeine and other methylxanthines can increase toxicity. Smoking induces metabolism, requiring dose adjustments. Consider alternative in acute exacerbations due to slow onset.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it can increase side effects.,Do not smoke or stop smoking without medical advice, as smoking affects how the drug works.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release tablets; swallow whole.,Keep a regular dosing schedule to maintain consistent blood levels.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOVENT vs AEROLATE, answered by our medical review team.
THEOVENT is a Bronchodilator that works by Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOVENT and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOVENT is: Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOVENT and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOVENT is classified as Category C. First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnan. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.